

Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities

Richard J. Bastin,[†] Michael J. Bowker,^{*,†,§} and Bryan J. Slater[‡]

Preformulation Department, Pharmaceutical Sciences, Aventis Pharma, Dagenham Research Centre (DRC), Rainham Road South, Dagenham, Essex RM10 7XS, UK, and World-Wide Physical Chemistry Department, Discovery Chemistry, Aventis Pharma, Dagenham Research Centre (DRC), Rainham Road South, Dagenham, Essex RM10 7XS, UK

Abstract:

Selection of an appropriate salt form for a new chemical entity provides the pharmaceutical chemist and formulation scientist with the opportunity to modify the characteristics of the potential drug substance and to permit the development of dosage forms with good bioavailability, stability, manufacturability, and patient compliance. Salts are most commonly employed for modifying aqueous solubility, however the salt form selected will influence a range of other properties such as melting point, hygroscopicity, chemical stability, dissolution rate, solution pH, crystal form, and mechanical properties. Where possible, a range of salts should be prepared for each new substance and their properties compared during a suitable preformulation program. Since it is normally possible to fully develop only one salt form, its properties should be appropriate to the primary route of administration and dosage form. An understanding of the influence of drug and salt properties on the finished product is essential to ensure selection of the best salt. The drug properties required for one dosage form may be quite different from those required for another. A well designed salt selection and optimisation study provides a sound base on which to build a rapid and economic product development programme.

Introduction

Modern drug discovery processes involve the screening of vast numbers of compounds that may have been made by the Company's research laboratories over many years. Added to these may be the many thousands of compounds that have been manufactured as libraries of structurally related series by "combinatorial chemistry" techniques. All of these compounds are generally dissolved in dimethylsulphoxide (DMSO) solution and screened in an enzyme- or receptor-based assay system. If the number of "hits" produced is large, the numbers are usually refined by further screening and selection until a manageable number of "leads" is available. Many of these leads will show only weak or moderate activity and further refinement and optimisation is invariably necessary. These optimisation procedures usually involve numerous structural modifications, aided by computational techniques, until a small number (usually 1–5) of highly active "candidates" remain.

* To whom correspondence should be sent.

[†] Preformulation Department, Pharmaceutical Sciences.

[‡] World-Wide Physical Chemistry Department, Discovery Chemistry.

[§] Current address: M. J. Bowker Consulting Ltd., 36, Burses Way, Hutton, Brentwood, Essex CM13 2PS, UK

These candidates are usually free bases, free acids, or neutral molecules, rather than their salts. Also, because of the generally higher molecular weights of modern drug substances and the increased use of DMSO solutions in the screening processes, it is becoming apparent that there is a tendency towards ever more lipophilic candidates being presented. Frequently, when first proposed as potential development candidates, they are often amorphous or partially crystalline as little effort has been made to investigate formal crystallisation procedures. The need for water-soluble candidates has been recognised^{1–4} for many years before the advent of 'combinatorial chemistry'.

Investigations into the Possibilities of Salt Formation

When first presented for initial preformulation investigations, normally the amount of drug substance available from Discovery Chemistry rarely exceeds 1 g. To maximize the amount of data gained from such small quantities, semi-micro techniques have been developed and are used regularly within our groups. Invariably, the first information generated for each candidate is the calculated pK_a value of each ionisable group in the molecule.^{5–8} This is quickly checked against the value determined experimentally on 1–2 mg of sample by potentiometric titration (e.g., Sirius Model GLpKa apparatus, Sirius Analytical Instruments Ltd.). Knowledge of the pK_a value enables potential salt forming agents (counterions) to be selected, for each candidate, based on lists that are available in the literature.^{2,9–11} For the formation of a stable salt, it is widely accepted that there should be a minimum difference of about 3 units between the pK_a value

- (1) Hirsch, C. A.; Messenger, R. J.; Brannon, J. L. *J. Pharm. Sci.* **1978**, *67*, 231.
- (2) Gould, P. L. *Int. J. Pharm.* **1986**, *33*, 201.
- (3) Morris, K. R.; Fakes, M. G.; Thakur, A. B.; Newman, A. W.; Singh, A. K.; Venit, J. J.; Spagnuolo, C. J.; Serajuddin, A. T. M. *Int. J. Pharm.* **1994**, *105*, 201.
- (4) Anderson, B. D.; Flora, K. P. In *The Practice of Medicinal Chemistry*; Wermuth, C. G., Ed.; Academic Press Ltd., 1996; Chapter 34.
- (5) *Remington: The Science and Practice of Pharmacy*, 19th ed.; Gennaro, A. R., Ed.; Mack Publishing Co.: Easton, Pennsylvania, 1993; Vol. II, p 1456.
- (6) Hammett, L. P. *Chem. Rev.* **1935**, *17*, 125.
- (7) Perrin, D. D.; Dempsey, B.; Serjeant, E. P. *pK_a Prediction for Organic Acids and Bases*; Chapman and Hall: London, 1981.
- (8) Albert, A. A.; Serjeant, E. P. *Ionization Constants of Acids and Bases*; Wiley: New York, 1984.
- (9) Wells, J. I. *Pharmaceutical Preformulation*, 2nd ed.; Ellis Horwood: Chichester, 1993; p 29.
- (10) Martindale, W. In *The Extra Pharmacopoeia*, 30th ed.; Reynolds, J. E. F., Ed.; The Pharmaceutical Press: London, 1993.
- (11) Berge, S. M.; Bighley, L. D.; Monkhouse, D. C. *J. Pharm. Sci.* **1977**, *66*, 1.

Table 1. Classification of common pharmaceutical salts

salt class	examples
Anions	
inorganic acids	hydrochloride, hydrobromide, sulfate, nitrate, phosphate
sulfonic acids	mesylate, ^b esylate, ^c isethionate, ^d tosylate, ^e napsylate, ^f besylate ^g
carboxylic acids	acetate, propionate, maleate, benzoate, salicylate, fumarate
anionic amino acids	glutamate, aspartate
hydroxyacids	Citrate, lactate, succinate, tartrate, glycollate
fatty acids	hexanoate, octanoate, decanoate, oleate, stearate
insoluble salts	pamoate (embonate), polystyrene sulfonate (resinate)
Cations	
organic amines	triethylamine, ethanolamine, triethanolamine, meglumine, ethylenediamine, choline
insoluble salts	procaine, benzathine
metallic	sodium, potassium, calcium, magnesium, zinc
cationic amino acids	arginine, lysine, histidine

^a Based on data from various sources.^{9–11} ^b Methane sulfonate. ^c Ethane sulfonate. ^d 2-Hydroxyethane sulfonate. ^e Toluene sulfonate. ^f Naphthalene sulfonate. ^g Benzene sulfonate.

of the group and that of its counterion, especially when the drug substance is a particularly weak acid or base. Occasionally, exceptions may be found where a salt has an acceptable stability, despite there being a smaller difference in the pK_a values.

A microplate technique has been developed for the screening of salts; this involves dissolving approximately 50 mg of sample in a suitable, volatile solvent and adding a fixed volume of this solution, containing about 0.5 mg of sample, into each microplate well. Concentrated solutions of each potential counterion in equimolar proportion, or other appropriate stoichiometric ratio, are prepared and a few microlitres of each is added sequentially to each well. Thus, all of the wells in line 1 (x -direction) will contain the same combination of sample and counterion 1; all of the wells in line 2 contain the same combination of sample and counterion 2, etc. Different, potential crystallising solvents can be investigated methodically in the y -direction. The wells are inspected using an inverted microscope (Leica, Model DMIRB) at regular intervals for the appearance of crystals. Occasionally, crystallisation can be promoted by evaporation of any excess solvent in some wells using a slow stream of dry nitrogen gas.

Once the combinations of counterion and solvent(s) are identified, studies at a slightly larger scale (usually 10–50 mg, occasionally up to 500 mg) can be initiated to confirm the suitability and viability of the crystals. These studies can help identify problems with low melting points, determined by hot-stage microscopy, and hygroscopicity, if processed on a suitable apparatus (e.g., Dynamic Vapour Sorption Analyser, model DVS-1, Surface Measurement Systems Ltd.). Frequently these studies can also give preliminary information on the existence of solvates and hydrates, especially if differential scanning calorimetry (DSC, Mettler Toledo DSC, model 820), thermal gravimetric analysis (TGA, Mettler Toledo TGA, model 850) and hot-stage microscopy are also used in the evaluation process.

In parallel with these studies, a preliminary high performance liquid chromatographic (HPLC) method is quickly developed to give an estimate of the purity of the sample, whilst infrared and other spectroscopic techniques may be

used to define the salt and the stoichiometry. Knowledge of the approximate purity is important at this stage as the presence of high levels of some impurities can often hinder crystallisation or alter the polymorphic form obtained.

Therefore, from these preliminary, small-scale studies, a range of potential salt formers and recrystallisation solvents can be quickly identified. Following further scale-up to gram quantities, more comprehensive data can be obtained to evaluate their suitability for use in formulations.

Choice of the Salt Former

Although the choice of salt is governed largely by the acidity or basicity of the ionisable group, safety of the counterion, drug indications, route of administration and the intended dosage form must also be considered. Toxicological and pharmacological implications of the selected salt former must be considered as well as the effects of the parent drug. Salt formers can be subdivided into a number of categories, depending upon their functionality and purpose. Some of the most frequently used examples are listed in Table 1.

The vast majority of salts are developed to enhance the aqueous solubility of drug substances. For weakly basic drug substances, salts of an inorganic acid (e.g., hydrochloride, sulphate, or phosphate), a sulphonic acid (mesylate or isethionate), a carboxylic acid (acetate, maleate or fumarate), a hydroxyacid (citrate or tartrate), or possibly an amino acid (arginine or lysine) could be considered. Hydrochloride salts have often been the first choice for weakly basic drugs, since as a consequence of the low counterion pK_a , salts can nearly always be formed, and recrystallisation from organic solvents is normally straightforward. However, the potential disadvantages of hydrochloride salts may include unacceptably high acidity in formulations (e.g., parenteral products), the risk of corrosion, less than optimal solubility due to the risk of salting out and the potential for poor stability if the drug is acid labile and hygroscopic.²

Occasionally, salts may be also prepared to decrease drug substance solubility for use in suspension formulations where very low solubility is necessary to prevent “Ostwald ripening”, for taste-masking, or to prepare an extended release product. Embonate salts have been used in suspension

Table 2. ^a Preformulation studies that are normally considered for comparison of salt forms and parent compound for oral dosage forms

test	suitable techniques	comments
dissociation constant and basic physico-chemical properties	potentiometry, solubility, UV spectroscopy	determine pK_a for parent drug
melting point	capillary m.pt., hot stage microscopy, differential scanning calorimetry	perform on each salt and compare to parent
aqueous solubility	overnight equilibration at 25 °C; analysis by UV spectroscopy or HPLC	Perform on each salt and compare to parent
pH of solution		Examine pH of saturated solution if quantities permit.
cosolvent solubility	overnight equilibration at 25 °C, analysis by UV spectroscopy or HPLC	Determine solubilities in ethanol, poly(ethylene glycol), propylene glycol and glycerol and compare to parent.
common ion effect on solubility	overnight equilibration at 25 °C in suitable media and analysis by UV spectroscopy or HPLC	compare solubility in demineralized water with 1.2% NaCl for salts and parent
hygroscopicity	use DVS apparatus or expose to various RH values and measure weight gain after 1 week	perform at 53, 93, and 97% RH, and other values of interest; assign hygroscopicity classification to each salt ¹³
intrinsic dissolution rate	use Wood's apparatus ¹⁴	compare dissolution rates at various pHs (can provide data on wettability)
crystal shape and appearance	SEM or optical microscopy	Compare crystal habits and levels of agglomeration
particle size	SEM and laser diffraction	Examine particle size distributions.
polymorphism/pseudopolymorphism	recrystallizations, HSM, DSC, TGA	preliminary exploration
powder properties	bulk density measurement	determine Carr's compressibility index
stability	various	perform on parent drug and undertake preliminary tests on appropriate salts

formulations to increase the duration of action (e.g., chlorpromazine embonate). On some occasions, the selection of a salt with only modest aqueous solubility may be more suitable for use in tablet products prepared by wet granulation since the use of highly soluble salts can be detrimental to the granulation process. Depending on the dose required, aqueous solubilities in the range 0.1–1.0 mg/mL will normally be sufficient to satisfy the dissolution requirements for standard, solid, oral dosage forms of drugs with good to moderate potency. However, for parenteral solution products, higher solubilities, perhaps 10 mg/mL or greater, depending on the required dose and dose volume, may be required. For parenteral formulations, the pH of solution (normally within an acceptable range of 3–10 for intravenous solution) should be monitored to help ensure that the formulation will be well tolerated.

Salts are also frequently prepared for the reasons other than solubility modification; it is frequently necessary to prepare a specific salt to either achieve adequate physical stability or for taste masking (e.g., dextropropoxyphene napsylate suspension). Manipulation of drug substance solubility by selection of salts may also be employed to modify the pharmacokinetic profile of the drug (e.g., benzathine penicillin and insulin zinc complexes used in parenteral formulations). Salt formation may be also advantageous where the melting point of the active moiety is low, and it is necessary to mill or micronise the active ingredient to achieve adequate homogeneity. A suitably stable salt may have a melting point that is 50–100 °C higher than the free acid or free base. Also, being more ionic, the crystals are

likely to be less plastic and more easily deformed by brittle fracture.

Scale-up of the Formation of Salts

The information from the preliminary crystallisation studies is communicated to the Process Chemistry group, who by this time will have started their investigations into possible manufacturing routes for each of the candidates remaining. At this stage in the development process, Process Chemistry usually aim to quickly manufacture 50–200 g of the one or two candidates that may remain to progress them towards initial clinical evaluation. The manufacturing route may be the same as used by the Discovery Chemistry group but usually is significantly different. The aims of both the Process Chemistry and Preformulation groups for the following 12–18 months is to collaborate extensively to ensure that, for the chosen candidate, there will be a viable synthetic route to the chosen form of the drug substance.

A significant portion of this batch is destined for the preparation of 3–4 g of each of the salts that were thought to be viable from the smaller-scale studies. A similar sized portion of the free base/acid is also taken for comparison purposes. The combination of individual studies undertaken on each of these 3–4 g portions varies depending on the type(s) of dosage form ultimately required for marketing. Occasionally, it may be necessary to undertake a pharmacokinetic evaluation of each salt in comparison with the free acid/base. The dosage forms most commonly used for the drug substances encountered during preliminary clinical investigations are tablets/capsules, inhalation dosage forms and injections.

Table 3. Tests to be considered for the evaluation of candidate salts

test to be considered	amount required, mg
Structural Analysis	
mass spectroscopy ^a	1
¹ H NMR ^a	5
¹³ C NMR ^a	25
Ir spectrum	1
UV spectrum	1
fluorescence spectrum ^a	1
elemental analysis	10
Physicochemical Properties	
melting range	2
pK _a ^a	5
C log P/log P ^a	5
preliminary polymorphism study	200–500
X-ray diffraction	20
aqueous solubility ^b	100
pH – solubility profile	500
cosolvent solubilities ^c	300
propellant solubility ^d	500
Physical Properties	
hygroscopicity	20
microscopy (SEM/optical)	10
particle size (Malvern)	100
size reduction (sonication)	300
Impurities (hplc)	
related substances ^a	10
degradation products ^a	10
chiral purity ^a	10
Stability Studies	
stability to hydrolysis (pH 2, 7, 10) ^a	15
stability to oxidation (peroxide/peracid) ^a	15
stability to photolysis ^a	15

^a Determined on free acid/base only. ^b Would include solubility in saline, 5% dextrose and some buffers. ^c Also solubilities in complexing agents/surfactant systems where appropriate. ^d Propellants and propellant/cosolvent systems for inhalation dosage forms.

Tables 2 and 3 show the types of tests normally chosen, the information that they can produce and the amount of sample normally required for these common dosage forms.

What to Develop: Salt or Free Acid/Base?

The results obtained from each of these tests are tabulated for the free acid/base, together with each of the salts, and discussed in detail between the Formulation Scientists, Preformulation Analysts, Physical Chemists, Process Chemists, and occasionally Pharmacokineticists. The Preformulation Scientists assess the relative merits of each form for use in the proposed clinical formulations and whether the properties such as solubility are adequate to give the high concentrations required in the various pre-clinical formulations. Process Chemistry need to assess the likely yield of each salt, as salt formation creates an additional step in the manufacturing process. Usually, the decision-making process results in the proposal of a single salt for further study, although occasionally it is seen that none of the salts have optimum properties, and two different salts can be proposed for in-depth study. Also, it is occasionally found that the overall properties of the free acid/base are much better than any of the salts. This occurs more frequently where the

candidate has a low pK_a value and the resulting salts are less stable than required or when the salts are particularly hygroscopic or when they exhibit complex polymorphism/pseudopolymorphism (hydration or solvation).

These relatively simple investigations give much useful information very quickly; it should be noted, however, that the preliminary polymorphism study is far from the in-depth study that is always undertaken later. This preliminary study uses a range of protic and aprotic solvents of widely differing polarity and will normally show the presence of a stable hydrate or solvate.

Once a decision is agreed upon within the group, a document that gives a précis of the discussions and the basis for the proposal is normally drafted for agreement by senior management. Examples of these salt selection studies are given below:

Example No. 1 (RPR 111423)

RPR 111423 is a candidate drug substance that has been evaluated for the treatment of symptoms related to infection by AIDS. It is a crystalline, very weak base with a pK_a at 4.25. A comprehensive screening of possible salts demonstrated only a monohydrochloride (RPR 111423A) and a mesylate (RPR 111423B) could be isolated as crystalline solids.

It was decided that the free base should be taken through the simple evaluation process in comparison with these two salts. It was expected that the drug substance could be required in the form of tablets or capsules, with an injection form needed for some pre-clinical studies and for the determination of absolute bioavailability in man. Because of its high activity in screening studies, there was a possibility that very low dose oral formulations might be needed. This may require micronised drug substance to enable content uniformity requirements to be met; this micronised material would also be expected to enhance dissolution.

The results from the relatively simple studies undertaken are given in Table 4. The two salts clearly demonstrated the predictable problems associated with a relatively low pK_a value; the salts were quite weak and dissociated to liberate the free base in media with pH values below the pK_a. The very low solubility of the free base resulted in immediate precipitation following dissociation. There was clear evidence for multiple polymorphism for each of the salts, and establishing the existence of a stable polymorph, or a suitable pseudopolymorph, may have been necessary before a decision could be made on which of the two salts could be developed further.

The corresponding results for the free base indicated that it appeared to be the better candidate; it showed no evidence of polymorphism, and it was not hygroscopic. The two major areas that required further investigation were whether it had sufficient solubility in gastrointestinal media and whether it could be micronised. Studies performed on samples of drug substance and on simple capsule formulations demonstrated that the dissolution rates of micronised free base were equivalent or superior to those of the salts under the same conditions.

Table 4. Comparison of some simple properties of RPR111423 and its two salts

test	result for RPR 111423 (base)		result for RPR 111423A (hydrochloride)		result for RPR 111423B (mesylate)	
	at 25 °C	at 37 °C	at 25 °C	at 37 °C	at 25 °C	at 37 °C
appearance	off-white to cream, crystalline powder		pale yellow, highly agglomerated powder		cream to pale yellow, highly agglomerated powder	
particle size by microscopy, μm	10–100 (large rhombic crystals)		2 × 1 (microcrystalline laths)		7 × 1 (microcrystalline laths)	
melting range, °C	241–244		242		210	
preliminary polymorphism study	no other form detected		at least four polymorphs detected; metastable forms revert to original on standing		at least six polymorphs detected; phase changes detected on grinding or micronisation; reverts to original form on heating	
other thermal behavior	nothing detected		loss of HCl detected at 110–120 °C		nothing detected	
aqueous solubility, mg/mL						
- at pH 1	11.6	14.7	25.7	28.2	131.4	204.1
- at pH 2	0.71	0.89	2.51	4.58	6.11	8.91
- at pH 4	0.03	0.05	0.05	0.13	0.01	0.02
- at pH 6	0.01	0.02	0.01	0.02	0.03	0.34
- at pH 6,8	0.01	0.02	0.01	0.02	0.01	0.02
- in demineralized water	0.01	0.02	0.36	0.99	0.33	0.50
pH of saturated solution, at 20 °C, in water	6.50		2.43		2.74	
addition of water to concentrate						
- at pH 2	no changes detected		some precipitation of free base		some precipitation of free base	
- at pH 4	no changes detected		extensive precipitation of free base		extensive precipitation of free base	
hygroscopicity (hygrostat for 14 days)	non-hygroscopic		slightly hygroscopic		moderately hygroscopic	
	<0.2% w/w water uptake at any RH		2.3% w/w uptake at 53% RH 22% w/w uptake at 97% RH		3.7% w/w uptake at 53% RH 32% w/w uptake at 97% RH	

Example No. 2 (RPR 127963)

RPR 127963 is a candidate drug substance that has been evaluated for the treatment of cardiovascular diseases; it is a crystalline, very weak base with a pK_a at 4.10. In common with most similar drug substances intended for the treatment of cardiovascular disease, it was considered that a high-dose (up to 250 mg) solid, oral dosage form and a correspondingly high-dose (up to 50 mg/mL) injection would be ultimately required. In line with our standard protocol, a comprehensive evaluation of possible salts was undertaken, and this demonstrated that five crystalline salts (a hydrochloride, a mesylate, a citrate, a tartrate, and a sulphate) could be readily produced. It was decided to quickly profile each of these salts in comparison with the free base. The results of these studies are given in Table 5.

When the anhydrous free base was evaluated, the existence of an additional mono-, di-, and trihydrate was found quite rapidly. It was shown that all four of these forms could be interconverted under conditions that might be expected to be found in granulation processing. The other potential problem with the anhydrate was the low melting point. In considering the results obtained for the various salts, the solubilities of the citrate and the tartrate were much lower than required for an injectable form and lower than ideal for high dosage formulations. An additional problem for the tartrate salt was the high hygroscopicity. Both of these salts were rejected before completion of the full evaluation. The hydrochloride salt was also shown to have several problems such as lower than ideal solubility, probable multiple polymorphism, and the formation of hydrates.

Thus, the mesylate and the sulphate were the two salts that remained; both had high melting points, excellent aqueous solubility, and were non-hygroscopic. The free base still remained a possible candidate, if a stable hydrate could be found. It was therefore decided to undertake some additional evaluations on these three forms; the results from these are presented in Table 6.

These additional results demonstrate a slight advantage in favour of the sulphate salt because of its greater solubility in cosolvents. This would give the formulator a better chance of achieving a higher dose in an injectable formulation. It was considered that the sulphate salt (RPR 127963E) could be studied further in the more detailed evaluations that would follow over the next few months. The mesylate or the free base (if a suitably stable hydrate could be found) would provide a possible back-up, should unforeseen problems arise.

Example No. 3 (RPR 200765)

RPR200765 is a candidate drug substance proposed for the treatment of rheumatoid arthritis. It is another crystalline, weak base with a pK_a of 5.3 which formed salts with a wide selection of counterions. It was expected that doses of 100–125 mg of RPR200765 in capsules would be required for clinical studies.

Early studies suggested that RPR200765 free base was unacceptable for use in solid, oral dosage forms due to a very poor aqueous solubility of approximately 10 $\mu\text{g/mL}$ and poor bioavailability in animal models. However, RPR200765 would form stable salts with hydrochloride, hydrobromide,

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.